StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
ResMed (RMD) PT Raised to $250 at Wolfe Research
August 12, 2022 5:06 AM
Wolfe Research analyst Mike Polark ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst PT Change
Next Articles
CLSA Downgrades ResMed (RMD:AU) (RMD) to Outperform (2), 'High near-term expectations may detract from long-term tailwinds'
August 15, 2022 6:31 AM
JPMorgan Downgrades ResMed (RMD) to Neutral
August 12, 2022 9:38 AM
